Who Are EnteroBiotix?

Redefining medicine through the human gut microbiome

Trillions of microbes call us home. These microbes and their repertoire of activity form the human microbiome, which performs a wide range of physiological functions that preserve our health and prevent disease. We are building a global pharmaceutical company focused on maximising the microbiome’s therapeutic potential. Our team is committed to dramatically improving healthcare through unlocking the therapeutic potential of the microbiome. We are developing and advancing three core product portfolios that build on the science of a medical treatment called faecal microbiota transplantation (FMT), with an initial focus on infections caused by antibiotic-resistant bacteria.

FMT involves transferring microbial communities from one person to another with the intention of treating a disease or infection in the recipient. When microbes from a healthy volunteer are introduced into the intestine of the recipient, those healthy microorganisms help to restore order, by overpowering the organisms that are causing the problem.

We formed EnteroBiotix after seeing how a lack of access to safe products was limiting the use of microbiota therapy. Our aim is to reduce the costs and inconveniences currently experienced by doctors wishing to offer the therapy. In the long term, our platform and product pipeline will facilitate research into the creation of microbial products that will completely remove the need for healthy donors.

Our donation facilities for collecting are accredited under ISO:9001/2008 while our processing and manufacturing of donor-derived microbiota is fully compliant with Good Manufacturing Practice (GMP), and fully licensed by the Medicines and Healthcare Products Regulatory Agency (MHRA).

How we are translating microbiome research into effective therapies for patients:

Minimally manipulated donor-derived products

Manipulated donor-derived products

Function to therapy reverse engineering